THE ROLE OF AUTOLOGOUS STEM CELL TRANSPLANTATION AND TUMOR LOAD IN MULTIPLE MYELOMA

2019 ◽  
Vol 37 ◽  
pp. 552-553
Author(s):  
A. Garifullin ◽  
S. Voloshin ◽  
S. Voloshin ◽  
S. Voloshin ◽  
A. Kuzyaeva ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Tumor Load

The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma

2019 ◽  
Vol 19 (10) ◽  
pp. 889-898 ◽  
Author(s):  
Almuth Maria Anni Merz ◽  
Maximilian Merz ◽  
Jens Hillengass ◽  
Sarah A. Holstein ◽  
Philip McCarthy
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Maintenance Therapy ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation

Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies

2020 ◽  
Vol 16 (2) ◽  
pp. 56-66 ◽  
Author(s):  
Ricardo D. Parrondo ◽  
Sikander Ailawadhi ◽  
Taimur Sher ◽  
Asher A. Chanan-Khan ◽  
Vivek Roy
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Residual Disease ◽  
Proteasome Inhibitors ◽  
Novel Therapies ◽  
Immunomodulatory Agents

Despite the evolution of the therapeutic arsenal for the treatment of multiple myeloma (MM) over the past decade, autologous stem-cell transplantation (ASCT) remains an integral part of the treatment of patients with both newly diagnosed and relapsed MM. The advent of novel therapies, such as immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies, has led to unprecedented levels of deep hematologic responses. Nonetheless, studies show that ASCT has an additive effect leading to additional deepening of responses. As the therapeutic agents for MM continue to evolve, the timing, duration, and sequence of their use in combination with ASCT will be crucial to understand to obtain the deepest response and survival benefit for patients with MM. This review aims to discuss the role of ASCT for the management of MM, with a particular focus on the role of ASCT in the context of novel therapies and minimal residual disease.

Sign in / Sign up

Export Citation Format

Share Document